ReviewEndocrine2017
Effect of cilostazol in treating diabetes-associated microvascular complications.
Review in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Nano-Cilostazol Mitigates Cisplatin-Induced Nephrotoxicity in Rats via Modulation of Oxidative Stress, Apoptosis, Pyroptosis, and miRNA-155 Signaling.Antioxidants (Basel, Switzerland) · 2026Article
- Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.Medical sciences (Basel, Switzerland) · 2024Review
- Cilostazol protects against gastric ulcers by regulating PPAR-γ, HO-1, PECAM-1, pErk-1, NF-κB, Bcl-2, and cleaved caspase-3 protein expression.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats.International journal of molecular sciences · 2024Article
- Pathogenesis, Assessment, and Treatment of Coronary Microcirculation Dysfunction.Arquivos brasileiros de cardiologia · 2024Review
- Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).MedComm · 2023Review
- Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease.Clinical drug investigation · 2023Observational
- Mechanistic Protective Effect of Cilostazol in Cisplatin-Induced Testicular Damage via Regulation of Oxidative Stress and TNF-α/NF-κB/Caspase-3 Pathways.International journal of molecular sciences · 2023Article
- Peripheral Nerve Denervation in Streptozotocin-Induced Diabetic Rats Is Reduced by Cilostazol.Medicina (Kaunas, Lithuania) · 2023Article
- The Role of Platelets in Diabetic Kidney Disease.International journal of molecular sciences · 2022Review
- A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease.Journal of personalized medicine · 2022Article
- The spectrum and systemic associations of microvascular dysfunction in the heart and other organs.Nature cardiovascular research · 2022Review
- Pharmacodynamic of cilostazol for anti-altitude hypoxia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Observational case-control study of small-fiber neuropathies, with regards on smoking and vitamin D deficiency and other possible causes.Frontiers in medicine · 2022Article
- Cilostazol protects against changes caused by streptozotocin-induced diabetic retinopathy.Arquivos brasileiros de oftalmologia · 2022Article
- Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.Stroke · 2021Review
- Cilostazol Ameliorates Peripheral Neuropathic Pain in Streptozotocin-Induced Type I Diabetic Rats.Frontiers in pharmacology · 2021Article
- Vascular Endothelial Repair and the Influence of Circulating Antiplatelet Drugs in a Carotid Coil Model.Journal of central nervous system disease · 2021Article
- Role of Phosphodiesterase in the Biology and Pathology of Diabetes.International journal of molecular sciences · 2020Review
- Mechanisms behind Retinal Ganglion Cell Loss in Diabetes and Therapeutic Approach.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCilostazol (Pletal), a phosphodiesterase-3 inhibitor, was approved in the United States in 1999 to reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition of phosphodiesterase resulting in anti-platelet, anti-inflammatory, and vasodilatory effects. Diabetes mellitus is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and macrovascular complications. This mini-review highlights the emerging evidence suggesting benefits of using cilostazol in treating microvascular complications associated with diabetes mellitus.
methodsA review of literature was conducted using PubMed and Embase databases focusing on cilostazol use in diabetes mellitus.
resultsCilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum soluble adhesion molecule-1 and monocyte chemoattractant protein-1. Cilostazol's anti-inflammatory actions predictably attenuate glomerular damage from increased leukocyte adherence. Additionally, cilostazol delayed renal dysfunction secondary to type 2 diabetes mellitus as albuminuria was reduced most likely resulting from inhibition of nuclear factor kappa-induced inflammatory and endothelial markers. Cilostazol's anti-inflammatory actions in addition to its vasodilatory actions relieved retinal hypoxia and decreased excessive production of retinal blood vessels suggesting benefit in diabetic retinopathy. Cilostazol did not improve neuropathy symptom scores signifying that it may not be as beneficial in patients with diabetic peripheral neuropathy without diabetic nephropathy or diabetic retinopathy.
conclusionsCilostazol's pleiotropic effects may be beneficial in patients with type 2 diabetes mellitus and diabetic nephropathy. Additional, larger studies need to be conducted to assess the benefits and risks of using cilostazol as an alternative agent in treating patients with diabetic microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.